Ongoing change in the treatment of HIV-associated malignancies in the HAART era

Antonello Malfitano, Giuseppe Barbaro, Giorgio Barbarini

Research output: Contribution to journalArticlepeer-review


Implementation of highly active antiretroviral therapy (HAART) has changed the epidemiology, clinical outcome and therapeutic approach of HIV-associated malignancies. Whereas Kaposi sarcoma and primary CNS non-Hodgkin lymphoma have decreased dramatically, systemic non-Hodgkin lymphoma incidence seems unchanged, perhaps increasing as with other tumor incidence. Owing to HAART-induced immune function preservation, response rates to chemotherapy and survival times in patients with HIV-associated malignancies have neared those observed in their HIV-negative counterparts. Hence, intensive regimens have been more and more extensively used with promising results. This may also apply to other therapeutic options, such as biotherapy, and procedures, such as stem cell rescue following high-dose chemotherapy or heterologous stem cell transplant, which have so far been precluded to HIV-infected subjects as a matter of fact. A trend toward a full assimilation of HIV-infected people with cancer and the general population with the same pathology is ongoing.

Original languageEnglish
Pages (from-to)283-293
Number of pages11
JournalExpert Review of Clinical Pharmacology
Issue number3
Publication statusPublished - 2009


  • Biotherapy
  • Chemotherapy
  • HIV
  • Lymphoma
  • Malignancy
  • Stem cell rescue

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Ongoing change in the treatment of HIV-associated malignancies in the HAART era'. Together they form a unique fingerprint.

Cite this